UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013	Jan. 31, 2012
Operating revenue:
Personalized oncology solutions	$ 473	$ 649	$ 1,850	$ 1,837
Translational oncology solutions	2,444	1,747	4,631	3,931
Total operating revenue	2,917	2,396	6,481	5,768
Costs and operating expenses:
Cost of personalized oncology solutions	676	528	2,030	1,463
Cost of translational oncology solutions	566	801	1,740	1,904
Research and development	592	930	1,415	2,558
Sales and marketing	658	623	2,047	1,885
General and administrative	1,145	1,287	3,484	4,421
Total costs and operating expenses	3,637	4,169	10,716	12,231
Loss from operations	(720)	(1,773)	(4,235)	(6,463)
Other (expense) income:
Change in fair value of warrant liability	(255)	66	(21)	354
Other (expense) income	(10)	(12)	(22)	(2)
Total other (expense) income	(265)	54	(43)	352
Loss before provision for income taxes	(985)	(1,719)	(4,278)	(6,111)
Provision for income taxes	5	0	6	0
Net loss	$ (990)	$ (1,719)	$ (4,284)	$ (6,111)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	$ (0.02)	$ (0.04)	$ (0.09)	$ (0.13)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	47,737,000	46,738,000	47,294,000	47,000,000